OHSU takes public stance against calls to close primate research center
On Wednesday, the university published an announcement addressing animal advocates' claims on why the Oregon National Primate Research Center should be shut down.
'Usually somebody blabs': Tony White's 2005 death still unsolved
People for the Ethical Treatment of Animals, better known as PETA, asked the National Institutes for Health's Office of Laboratory Animal Welfare to investigate the OHSU center in mid-April. The organization's revealed a 4-year-old monkey died a 'painful death' from sepsis last year after people at the Beaverton facility ignored her symptoms.
The Physicians Committee for Responsible Medicine has also slammed the research center, referring to it as a the university could replace by further investing in patient care.
In response, OHSU said the claim 'compares apples to oranges.' The institution noted the facility is mostly funded by federal grants that only cover specific research efforts, which improve patient care by identifying new ways to treat diseases.
The university also pushed back on animal advocates' argument that the research is cruel and unnecessary.
'While scientific advancements have introduced alternative non-animal models, this technology cannot fully replicate the complexity of a living system at this time,' OHSU . 'Nonhuman primate research remains critical for studying conditions such as Alzheimer's, Parkinson's, infectious diseases and reproductive health — areas where animal-free methods cannot yet provide complete answers.'
May Day rally in Salem defends immigrant workers' rights, opposes sanctuary city cuts
The institution noted that animal research is heavily regulated by federal authorities. OHSU also claimed its primates grow up with their social groups and form bonds with researchers in the facility.
Many of the university's points were shared in the rally that researchers held on the west campus last month, after Oregon Gov. Tina Kotek urged leaders to close the primate facility.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Study Finds Special Brain Traits of 'SuperAgers.' Here's How They Avoid Dementia
A study that began in the year 2000 is finally paying off. Northwestern University's SuperAger program has been in the works for over 25 years, and a new report in the Journal of the Alzheimer's Association is detailing what the group has found. Published on August 7, the report details the scope of the study and its results so far — 25 years out since the start. 290 people signed up to be studied in that time, all over 80 years old and cognitively well. Participants are tested for a high delayed word recall ability, signifying a higher memory capacity at an older age. These seniors that show exceptional memory are labeled "SuperAgers". Of the 290 participants, 79 allowed scientists to autopsy their brains after passing away. Because of this, researchers were able to make a connection between dementia, particularly Alzheimer's, and the structure of the brain. "Neurotypical seniors ≥ 80 years of age have significant and widespread cortical thinning compared to neurotypical 50- to 60-year-olds," the report reads, "Superagers, on the other hand, showed no cortical thinning compared to the younger controls." The brain — particularly the cerebral cortex — naturally thins as a person ages, but Northwestern's report shows that may happen less quickly in some people than in others. "It appears that cortical thinning is unavoidable," the report states, "but that it is probably much slower in superagers." Further, researchers reported that superagers' brains tend to develop few or zero amyloid plaques and tau tangles, which are two tell-tale signs of Alzheimer's disease. While no specific cause has been determined, researchers believe they're a bit closer to understanding dementia. What is dementia? Dementia is a decline in memory or mental capacity, usually found in senior citizens. Alzheimer's is the most common form of dementia, affecting around 11% of those 65 and older. There are various factors that scientists believe could lead to an increased chance of developing Alzheimer's or dementia as a person ages. Some of these factors, as found in the study by Northwestern University, are structural and genetic. Others, though, may come from a person's lifestyle. Research shows that traumatic brain injuries earlier in life, high blood pressure, untreated depression, and hearing loss may help onset dementia. Low physical activity and few meaningful personal connections may also exasperate the degenerative Finds Special Brain Traits of 'SuperAgers.' Here's How They Avoid Dementia first appeared on Men's Journal on Aug 7, 2025 Solve the daily Crossword
New York Post
2 days ago
- New York Post
Trump can rein in healthcare costs AND win medical breakthroughs — here's how
Of all the problems bedeviling the American healthcare system, the high cost of pharmaceuticals is one of those most commonly cited by patients. Polling finds that most Americans think drugs are too expensive, and they're often right — even if pricey medications beat alternatives like surgery, hospitalization or living with pain. President Donald Trump has promised to implement healthcare reforms that both increase innovation and improve affordability. Advertisement Some see these as contradictory pursuits — but when it comes to pharmaceuticals, both of the president's goals can be achieved at the same time. This week the two of us, along with a team of top health and economic experts, launched Most Favored Patients, a working group aimed at developing reforms that will lower drug prices in ways that won't hinder or delay new drug development. Before we suggest policies that could work, let's be clear about what doesn't: government-mandated price controls. Advertisement Top-down edicts that remove the profit motive from drug research and development will do more harm than good, impeding the race to identify cures for cancer, Alzheimer's, Parkinson's, epilepsy and other cruel diseases. It's a short-sighted solution, too: It ignores the reality that 93% of US prescriptions are for very cheap generics — indeed, cheaper here than abroad — that emerge after innovators earn the necessary returns on their investments. Instead, let's try some innovations that make both medical and economic sense. First, do the easy stuff first and allow patients to buy medicines from pharmaceutical companies directly. Advertisement Our recent poll of 1,000 battleground-state voters found overwhelming 86% support for this concept, which would lower drug prices by avoiding expensive retail markups imposed by insurance companies and others. Most voters also favor Trump's intention to rein in costly middlemen like the highly concentrated pharmacy benefit manager industry, which negotiates drug prices for insurance companies. We also must require foreign countries to pay their fair share for medical innovations developed in the United States — that is, nearly all of them. Trump can use his NATO negotiations as a model here: Just as he has required Europe to pony up more for the benefits of NATO security through minimum levels of military spending, he could convince trading partners to spend more of their GDP on new drugs. Advertisement Right now, more than 70% of global pharmaceutical earnings come from the United States, even though we generate less than a quarter of global GDP. We annually spend $13,000 on healthcare per capita, while the rest of the developed world spends far less than $10,000 — partly because we allow more free-market healthcare pricing than other nations do. Trump is already implementing some of these reforms in his America First trade deals, securing some $300 billion worth of foreign commitments for new domestic pharmaceutical R&D, manufacturing and workforce investments. These commitments share the burden of finding cures that will benefit all of humanity — while fueling the American research engine that justifies the investments. Next, the Food and Drug Administration must thoroughly overhaul its antique, snail's-pace drug approval process: Many potential wonder drugs developed by small biomedical firms are shelved when that process' exorbitant costs and delays drain their capital. The FDA should fast-track experimental drugs for crippling and lethal diseases, and should expedite 'Right To Try' rules to get promising drugs to the people who need them. In addition, we believe the FDA should loosen its regulations and use economic criteria, not just clinical ones, to determine whether a drug may be fast-tracked for approval: Put simply, cheaper drugs should be allowed to come to market faster. Advertisement Finally, we're confident that price transparency in drugs and all other medical services would help drive prices down and encourage more comparison-shopping by patients. We don't buy food or gas or homes without knowing their price — but that's too often the case with drugs, hospitals and medical procedures. Republicans have been missing out on the political benefits of seizing on common-sense reforms like these. Advertisement Voters consistently view the GOP as being less caring and less reliable on solving our nation's healthcare concerns. That's made them cower. They keep their mouths shut and flee from any discussion of voters' valid complaints — and often lose elections as a result. As the midterms approach, Republicans who promote innovation with our Most Favored Patient proposals will help bring down costs, ensure American biomedical innovative supremacy, and save lives. Advertisement Everyone is on board with that. Stephen Moore is a co-founder of Unleash Prosperity, where Tomas Philipson is a senior research fellow.
UPI
2 days ago
- UPI
Researchers: Small traces of lithium may help prevent Alzheimer's
A Harvard Medical School and Rush University study suggests tiny amounts of lithium may help protect the brain from Alzheimer's and signs of aging. Photo by Adobe Stock/HealthDay News Tiny amounts of lithium -- a natural metal -- may help protect the brain from Alzheimer's and signs of aging, new research shows. Scientists at Harvard Medical School and Rush University found that when mice were fed a low-lithium diet, their brains developed more inflammation and signs of aging accelerated. The findings were published Wednesday in the journal Nature. Turns out, lithium may play a critical role in how the brain stays healthy, the researchers found. In the study, they compared normal mice to mice bred to develop brain changes linked to Alzheimer's, including a build-up of sticky proteins. Mice on low-lithium diets developed problems more quickly, while those given a specific lithium compound called lithium orotate saw signs of brain improvement. When given lithium orotate, mice had fewer memory problems and fewer of the sticky clumps known as beta amyloid plaques. In people, those plaques are hallmarks of Alzheimer's. Many people know lithium as a drug used to treat bipolar disorder and depression. It's been used for decades. But this study suggests that very small amounts of lithium are naturally present in the body, and it may be essential for brain health. Researchers suspect that beta amyloid binds to lithium and prevents it from reaching brain cells that need it. Without enough lithium, cells called microglia, which help clean up waste in the brain, stop working properly. This creates a sort of cycle: As beta amyloid builds up, even less lithium is available and the brain has a harder time clearing the damaging proteins. In the first stage of the study, scientists tested brain tissue and blood samples from people with and without Alzheimer's. They looked at 27 metals and found a key difference: Lithium levels were much lower in the brains of people with memory problems. They repeated this test using brain samples from multiple hospitals and universities and found the same results. "At first, frankly, we were skeptical of the result because it wasn't expected," Dr. Bruce Yankner, a professor of genetics at Harvard, told CNN. Experts warn that people should not take lithium supplements without medical advice. The doses used in this study were about 1,000 times lower than the doses used to treat mental illnesses such as bipolar disorder. "A mouse is not a human. Nobody should take anything based just on mouse studies," Yankner said. "The lithium treatment data we have is in mice, and it needs to be replicated in humans. We need to find the right dose in humans," he added. Still, the findings are promising. Mice who received low doses of lithium orotate did not show any signs of toxicity or organ damage. Yankner hopes human trials will start soon. Many healthy foods contain small amounts of lithium. These include: Leafy green vegetables Nuts and legumes Certain spices like turmeric and cumin Some mineral waters Previous studies have hinted at lithium's benefits. One large Danish study found people with higher lithium levels in their tap water were less likely to be diagnosed with dementia. Another study in the U.K. found people prescribed lithium were about half as likely to get Alzheimer's as those who were not. Ashley Bush, a neuroscientist in Australia, wrote an editorial that accompanied the new research. He said it presents "compelling evidence that lithium does in fact have a physiological role and that normal aging might impair the regulation of lithium levels in the brain." Yankner pointed to the possible benefit. "It is a potential candidate for a common mechanism leading to the multisystem degeneration of the brain that precedes dementia," he told CNN. "It will take a lot more science to determine whether this is a common pathway... or one of several pathways," to Alzheimer's, he added. "The data are very intriguing." More information The Mayo Clinic has more on lithium. Copyright © 2025 HealthDay. All rights reserved.
